Malhamé Isabelle, Dong Susan, Syeda Ambreen, Ashraf Rizwana, Zipursky Jonathan, Horn Daphne, Daskalopoulou Stella S, D'Souza Rohan
Department of Medicine, McGill University Health Centre.
Research Institute of the McGill University Health Centre, Montréal, Quebéc.
J Hypertens. 2023 Jan 1;41(1):17-26. doi: 10.1097/HJH.0000000000003310. Epub 2022 Nov 2.
Addressing volume expansion may improve the management of hypertension across the pregnancy continuum. We conducted a systematic review to summarize the evidence on the use of loop diuretics in the context of hypertensive disorders during pregnancy and the postpartum period.
Medline, Embase, Cochrane library, ClinicalTrials.gov, and Google Scholar were searched for original research articles published up to 29 June 2021. Of the 2801 results screened, 15 studies were included: eight randomized controlled trials, six before-after studies, and one cohort study. Based on random effects meta-analysis of before-after studies, antepartum use of loop diuretics was associated with lower DBP [mean difference -17.73 mmHg, (95% confidence intervals -34.50 to -0.96); I2 = 94%] and lower cardiac output [mean difference -0.75 l/min, (-1.11 to -0.39); I2 = 0%], with no difference in SBP, mean arterial pressure, heart rate, or total peripheral resistance. Meta-analysis of randomized controlled trials revealed that postpartum use of loop diuretics was associated with decreased need for additional antihypertensive patients [relative risk 0.69, (0.50-0.97); I2 = 14%], and an increased duration of hospitalization [mean difference 8.80 h, (4.46-13.14); I2 = 83%], with no difference in the need for antihypertensive therapy at hospital discharge, or persistent postpartum hypertension.
Antepartum use of loop diuretics lowered DBP and cardiac output, while their postpartum use reduced the need for additional antihypertensive medications. There was insufficient evidence to suggest a clear benefit. Future studies focusing on women with hypertensive pregnancy disorders who may most likely benefit from loop diuretics are required.
解决容量扩张问题可能会改善整个孕期高血压的管理。我们进行了一项系统评价,以总结在妊娠和产后高血压疾病背景下使用袢利尿剂的证据。
检索了Medline、Embase、Cochrane图书馆、ClinicalTrials.gov和谷歌学术,查找截至2021年6月29日发表的原始研究文章。在筛选的2801项结果中,纳入了15项研究:8项随机对照试验、6项前后对照研究和1项队列研究。基于前后对照研究的随机效应荟萃分析,产前使用袢利尿剂与较低的舒张压相关[平均差-17.73 mmHg,(95%置信区间-34.50至-0.96);I² = 94%]和较低的心输出量[平均差-0.75 l/min,(-1.11至-0.39);I² = 0%],收缩压、平均动脉压、心率或总外周阻力无差异。随机对照试验的荟萃分析显示,产后使用袢利尿剂与减少额外抗高血压药物的需求相关[相对风险0.69,(0.50 - 0.97);I² = 14%],以及住院时间延长[平均差8.80 h,(4.46 - 13.14);I² = 83%],出院时抗高血压治疗的需求或持续性产后高血压无差异。
产前使用袢利尿剂可降低舒张压和心输出量,而产后使用可减少额外抗高血压药物的需求。没有足够的证据表明有明显益处。需要针对最可能从袢利尿剂中获益的妊娠高血压疾病女性开展未来研究。